Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-272-7 | CAS number: 13718-26-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute oral toxicity: LD50 = 169 mg/kg bw (OECD 401; GLP; female rats)
Acute inhalation toxicity: LC50 = 3.73 mg/ L air (OECD 403; GLP; female rats)
Acute dermal toxicity: LD50 > 2500 mg/kg bw (OECD 402; GLP; read-across from potassium vanadium trioxide)
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1993-12-20 to 1994-01-24
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Minor deviation from the OECD 401 guideline occurred, but this had no impact on the results of the study: - information about individual body weights was not given.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- 1987-02-24
- Deviations:
- yes
- Remarks:
- see rational for reliability
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- signed 1991-07-25
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS - Sprague-Dawley/Crl:CD R BR
- Source: Charles River Deutschland GmbH, Niederlassung Sulzfeld, Sandhofer Weg 7, D-97633 Sulzfeld
- Age at start of adaptation: 25 - 30 days
- Weight at start of administration: 170 - 200 g
- Fasting period before study: feeding was discontinued approximately 16 hours before administration. Only tap water was offered ad libitum.
- Housing: granulated textured wood (Granulate type A2, supplier: BRANDENBURG, D-49424 Goldenstedt) was used as bedding material for the cages. The animals were kept in groups of 2 - 3 during housing in MAKROLON cages (type III).
- Diet: standardized diet Altromin 1324 (ALTROMIN GmbH, D-32791 Lage/Lippe)
- Water (ad libitum): tap water
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature: 22°C ± 3°C (maximum range)
- Relative humidity: 60% ± 20% (maximum range)
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- other: 0.8% aqueous hydroxypropyl-methylcellulose gel
- Details on oral exposure:
- VEHICLE
- Batch no.: MM90100512E
MAXIMUM DOSE VOLUME APPLIED: 20 mL/kg bw (dose interval factor: 2.15)
DOSAGE PREPARATION: The test substance was disollved or suspended in the vehicle. - Doses:
- 46.4, 100, 215 and 464 mg/kg bw
- No. of animals per sex per dose:
- 5 males / 5 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: observations were performed immediately, 5, 15, 30 and 60 minutes, as well as 3, 6 and 24 hours after administration. During this follow-up period, the clinical signs were observed at least once a day until all symptoms subsided, and thereafter each working day. Observations on mortality were made at least once daily with appropriate actions taken to minimise loss of animals during the study. Individual body weights were recorded before administration of the substance, thereafter in weekly intervals up to the end of the study, and at death. Changes in the weights were calculated and recorded as precisely as possible.
- Necropsy of survivors performed: yes, at the end of the experiments all surviving animals were sacrificed, dissected and inspected macroscopically. All gross pathological changes were recorded. From animals which survive 24 hours or longer a microscopic examination of all organs which show evident lesions is performed, if applicable. Autopsy and macroscopic inspection of the animals which died prematurely was carried out as soon as possible after exitus. - Statistics:
- The LD50 was calculated according to FINNEY (Probit analysis).
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 212 mg/kg bw
- Based on:
- test mat.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 169 mg/kg bw
- Based on:
- test mat.
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 183 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 140 - <= 238
- Mortality:
- 46.4 mg/kg bw: no mortality
100 mg/kg bw: 1 female (day 3.5)
215 mg/kg bw: 3 males and 3 females (24 hours - 48 hours)
464 mg/kg bw: all males (24 hours - 48 hours) and all females (4 hours - 24 hours) - Clinical signs:
- other: 46.4 mg/kg bw: none 100 mg/kg bw: weak reduced motility (60 minutes - 24 hours; all males and females); weak ataxia (60 minutes - 24 hours; all males and females); weak dyspnoea (60 minutes - 24 hours; all males and females) 215 mg/kg bw: weak reduced m
- Gross pathology:
- 46.4 and 100 mg/kg bw: no pathological findings
215 mg/kg bw: 3 males and 3 females had a slightly reddened gastro-intestinal wall
464 mg/kg bw: all males and all females had a slightly reddened gastro-intestinal wall - Interpretation of results:
- Toxicity Category III
- Conclusions:
- LD50 (male rats): 212 mg/kg bw
LD50 (female rats): 169 mg/kg bw
LD50 (male and female rats): 183 mg/kg bw (confidence limits: 140 - 238 mg/kg bw)
No-effect dose-level: 46.4 mg/kg bw
Lowest lethal dose-level: 215 mg/kg bw (males) and 100 mg/kg bw (females)
According to the EC-Regulation 1272/2008 and subsequent adaptations, the test item is classified as as acutely toxic via the oral route (Category 3).
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 169 mg/kg bw
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1994-01-10 to 1994-02-15
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Minor deviations from the OECD 403 guideline occurred, but they had no impact on the results of the study: - the humidity was <17 % for optimal dust distribution (recommended 30-70%) - the air change rate was slightly greater than 15/h. - no 95th percentile was calculated.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Version / remarks:
- 1981-05-12
- Deviations:
- yes
- Remarks:
- see rational for reliability
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- signed 1991-07-25
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS - Sprague-Dawley/Crl:CD R BR
- Source: Charles River Wiga GmbH, Niederlassung Sulzfeld, Sandhofer Weg 7, D-97633 Sulzfeld
- Age at start of adaptation: 35 - 50 days
- Weight at study initiation (immediately before exposure): males. 173 - 199 g; females: 173 - 192 g
- Fasting period before study: food was discontinued approximately 16 hours before exposition.
- Housing: granulated textured wood (type 2, supplied by: Johannes Brandenburg, D-49424 Goldenstedt-Arkeburg) was used as bedding material. During the 14- day observation period the animals were kept in group-caged by sex in groups of two or three in MAKROLON cages (type III).
- Diet (ad libitum): standardized diet for rats ALTROMIN 1324 (ALTROMIN GmbH, D-32791 Lage/Lippe)
- Water (ad libitum): tap water
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature: 22°C ± 3°C (maximum range)
- Relative humidity: 50% ± 20% (maximum range)
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- inhalation: dust
- Type of inhalation exposure:
- nose only
- Vehicle:
- clean air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus/Exposure chamber volume/Method of holding animals in test chamber: the study was carried out using a dynamic inhalation apparatus (air changes/h. ≥ 12 x) with a nose only exposure of the animals according to KIMMERLE & TEPPER (RHEMA-LABORTECHNIK, D-65719 Hofheim/Taunus).
The apparatus consists of a cylindrical exposure chamber (volume 40 L) which holds a maximum of 20 animals in pyrex tubes at the edge of the chamber in a radial position.
- System of generating particulates/aerosols: the dust was generated with a rotating brush dust generator (RBG 1000, PALAS GmbH Partikel und Lasermesstechnik, D-76131 Karlsruhe. The generator was fed with compressed air from a compressor (air was taken from the surrounding atmosphere of the laboratory room and filtered using an in-line disposable gas-filter). At the bottom of the exposure chamber the air was sucked off at a lower rate than it was created by the dust generator in order to produce a homogenous distribution and a positive pressure in the exposure chamber.
Different concentrations were established by means of a combination of different settings of the dosing apparatus and different values of air flow.
- Method of particle size determination: an analysis of the particle size distribution was carried out during the first and during the second half of the exposure period using a cascade impactor according to MAY (MAY, K.R. 'Aerosol impaction jets', J. Aerosol Sci. 6, 403 (1975), RESEARCH ENGINEERS Ltd., London N1 5RD, UK).
The dust from the exposure chamber was sucked through the cascade impactor for 2 to 5 minutes at a constant flow rate of 5 L/min. The slides were removed from the impactor and were weighed on an analytical balance (SARTORIUS, type 1601 004, precision 10 µg).
The mass median aerodynamic diameter (MMAD) was estimated by means of nonlinear regression analysis (LITCHFIELD & WILCOXON). The 32 µm particle size range and the filter (particle size range < 0.5 µm) were not included in the determination of the MMAD in order not to give undue weight to these values.
- Treatment of exhaust air: the exhaust air was sucked through 3 gas wash-bottles filled with tap water. The outlet of the inhalation apparatus was in a DIN certified fume cupboard.
- Temperature, humidity, air flow and oxygen content: a manometer and an air-flow (Rotameter, ROTA Apparate- und Maschinenbau, D-79664 Wehr/Baden) were used to control the constant supply of compressed air and the exhaust, respectively. Flow rates were checked once per hour and corrected if necessary. Air changes per hour were 23 - 47.5.
The oxygen content in the inhalation chamber was 19%. The oxygen content was determined at the beginning and at the end of the exposure with a DRÄGER Oxygenanalysis test set (DRÄGER Tube Oxygen 67 28 081).
The exposure system was installed in a facility with a room temperature of 22°C ± 2°C and a relative humidity of 50% ± 20%.
Temperature (GTH 1200 Digital Thermometer, GREISINGER ELECTRONIC GmbH, D-93128 Regenstauf) and humidity (Sekunden-Hygrometer Typ 6100, TESTOTERM) within the inhalation chamber were measured and recorded once per hour (Temperature: 18.9°C - 21.9°C; humidity: 10.4% - 16.6%). Humidity within the inhalation chamber had to be kept at this low value in order to ensure an adequate particle size distribution.
Exposition started by locating the rats into the exposure chamber after equilibration of the chamber concentration for at least 15 minutes.
TEST ATMOSPHERE
- Brief description of analytical method used: the dust concentration in the inhalation chamber was measured with an air sample filter (SARTORIUS filter; Minisart SM 17598; 0.45 µm) and pump (Vacuubrand GmbH + Co., Otto-Schott-Straße 25, D-97877 Wertheim/Main). Dust samples were taken at least one every hour.
By means of a piece of silicon tubing, the filter was connected to an air flow meter (Rotameter, ROTA Apparate- und Maschinenbau, D-79664 Wehr/Baden) attached to the pump. The filters were weighed before and after sampling (accuracy: 10 µg)
- Samples taken from breathing zone: yes
TEST ATMOSPHERE
- MMAD (Mass median aerodynamic diameter):
0.48 mg/L air: 5.10 µm
2.58 mg/L air: 6.57 µm
4.13 mg/L air: 7.11 µm
- Respirable amount (particle size ≤4 µm):
0.48 mg/L air: 0.24 mg/L air
2.58 mg/L air: 0.62 mg/L air
4.13 mg/L air: 0.97 mg/L air - Analytical verification of test atmosphere concentrations:
- yes
- Remarks:
- refer to "Details on inhalation exposure" above
- Duration of exposure:
- 4 h
- Concentrations:
- Nominal concentrations:
2.11, 13.53 and 26.52 mg/L air
Actual concentrations:
0.48 ± 0.04, 2.58 ± 0.22 and 4.13 ±0.13 mg/L air
4.13 mg/L air was the highest amount of the test substance that could be generated in the inhalation chamber. - No. of animals per sex per dose:
- 5 males / 5 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: during and following exposure, observations were made and recorded systematically; individual records were maintained for each animal. A careful clinical examination was made at least once each day until all symptoms subsided, thereafter each working day.
Observations on mortality were made at least once daily with appropriate actions taken to minimize loss of animals to the study, e.g. necropsy or refrigeration of those animals found dead and isolation or sacrifice of weak or moribund animals.
Individual body weights of the animals were determined immediately before the exposure, after 1 week and at study termination.
- Necropsy of survivors performed: yes; necropsy of all animals was carried out and all gross pathological changes were recorded. Histopathology was not carried out as no relevant lesions were observed macroscopically. - Statistics:
- The LC50 was calculated by means of regression analysis.
- Sex:
- male
- Dose descriptor:
- LC50
- Effect level:
- 4.93 mg/L air (analytical)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Remarks on result:
- other: Slope: 11.0
- Key result
- Sex:
- female
- Dose descriptor:
- LC50
- Effect level:
- 3.73 mg/L air (analytical)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Remarks on result:
- other: Slope: 19.2
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- 4.13 mg/L air (analytical)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Remarks on result:
- other: Slope: 15.1
- Sex:
- male
- Dose descriptor:
- LC0
- Effect level:
- 4.13 mg/L air (analytical)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Sex:
- female
- Dose descriptor:
- LC0
- Effect level:
- 4.13 mg/L air (analytical)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Mortality:
- All deaths after end of exposure
0.48 and 2.58 mg/L air: no mortality
4.13 mg/Lair: 1 male (48 hours) and 4 females (0 - day 5) - Clinical signs:
- other: All symptoms after end of exposure. 0.48 mg/L air: none 2.58 mg/L air: weak lacrimation (0 minutes; 1 male); weak salivation (0 minutes; 4 males and 4 females); nose and/or snout reddened (0 minutes; 4 males and 4 females); weak apathy (15 - 60 minutes;
- Body weight:
- No inhibition of body weight gain was observed.
- Gross pathology:
- 0.48 and 2.58 mg/L air: no pathological findings
4.13 mg/L air: nose with haemorrhagic incrustation and small intestines distended were observed at 4.13 mg/L air in 1 deceased female, lungs with dark-red foci and a dark red liver were observed in another deceased female. These changes can be regarded as unspecific effects which usually occur after the inhalation exposure to a dust. - Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- LC50 (male rats): 4.93 mg/L air (analytical)
LC50 (female rats): 3.73 mg/L air (analytical)
LC50 (male and female rats): 4.13 mg/L air (analytical)
According to the EC-Regulation 1272/2008 and subsequent adaptations, the test item is classified acutely toxic via the inhalation route (Category 4).
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 3 730 mg/m³ air
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Data waiving:
- other justification
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 500 mg/kg bw
Additional information
Read across-acute dermal toxicity performed with KVO3:
KVO3and NaVO3are vanadates with similar solubility potential, i.e. 124 g/L at pH 9 and 215 g/L at pH 8.8, respectively, and similar V content, i.e. 36.9% and 41.8%, respectively. Potassium and sodium are (i) ubiquitous in the environment (air, soil and water), (ii) key nutrients and intrinsically present in the human body due to a natural background in all dietary sources, and (iii) normal constituents of all body fluids and main blood minerals, and maintain electrolyte or acid-base (pH) balance as well as a proper fluid. Potassium and sodium belong to the ten most common elements in the human body, by mass ca. 0.4% and 0.2%, respectively, and functions in the body cover cellular transport, water regulation, blood pressure control, nerve conduction, muscular contraction as well as enzymatic reactions and other metabolic activities. In consequence, because of the intrinsic nature of sodium and potassium as endogenous physiological compounds and because of similar solubility characteristics of KVO3and NaVO3, read-across of dermal toxicity data from KVO3to NaVO3is justified.
Acute oral toxicity
Sodium metavanadate is toxic if swallowed as the LD50 (rats, females) as determined in the reliable GLP-study (Leuschner, 1994) is 169 mg/kg bw.
Acute inhalation toxicity
Sodium metavanadate is harmful if inhaled as the LC50 (rats, females) is 3.73 mg/L air (analytical).
Acute dermal toxicity
Acute toxicity testing via the dermal route is not considered to be scientifically justified. Following the HERAG guidance for metals and metal salts (see section 7.1.2 of the technical dossier, dermal absorption), a dermal absorption rate in the range of maximally 0.1-1.0 % can be anticipated. Dermal absorption in this order of magnitude is not considered to be “significant”. Furthermore, results of a dermal toxicity study of the structural analogue KVO3 also indicate a lack of toxicity via the dermal route.
Justification for classification or non-classification
Sodium metavanadate requires classification as toxic if swallowed (Category 3) and harmful if inhaled (Category 4) according to Regulation (EC) 1272/2008. Classification of sodium metavanadate for acute toxicity via the dermal route is not required according to Regulation (EC) 1272/2008.
Specific target organ toxicant (STOT) – single exposure: oral and inhalation
The classification criteria according to regulation (EC) 1272/2008 as specific target organ toxicant (STOT) – single exposure, oral and inhalation are not met since no reversible or irreversible adverse health effects (local or/and systemic) were observed below lethal levels in addition to this effects which were responsible for the death of the animals. Hence, no classification required.
Specific target organ toxicant (STOT) - single exposure: dermal
The classification criteria according to Regulation (EC) 1272/2008 as specific target organ toxicant (STOT) – single exposure dermal are not met since any adverse health effects, including reversible and irreversible, were not observed immediately or delayed after exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.